Anti-CRIPTO, CT (Teratocarcinoma-derived Growth Factor 1, Epidermal Growth Factor-like Cripto Protei

The human cDNA for CRIPTO, isolated from a teratocarcinoma cell line, encodes a protein of 188aa. The central section has structural similarities with the human transforming growth factor alpha and epidermal growth factor (EGF). CRIPTO transcripts are detected only in undifferentiated cells and disappear after cell differentiation induced by retinoic acid treatment. The EGF-CFC (Cripto, Frl1, and Cryptic) gene family has an important role in vertebrate development. Cripto is required for germ-layer formation and the correct positioning of the anterior-posterior axis in mic, Cryptic (CFC1) is necessary for assignment of the left-right axis. Prior to gastrulation, Cripto expression is initially symmetric and uniform in the epiblast, and then becomes asymmetric in a proximal-distal gradient. Cripto gene when rendered inactive is fatal in the murine model. Cripto and Cryptic are essential cofactors for Nodal family proteins, which transduce signals for mesoderm development. Cryptic protein is required for appropriate symmetry development in humans. TDGF1, like CFC1, is an EGF-CFC family member and required coreceptor in NODAL signaling, a developmental program implicated in midline, forebrain, and left-right axis development in model organisms. A mutation in the conserved CFC domain of the TDGF1 gene has been identified in a patient with midline anomalies of the forebrain. The mutant protein was inactive in a zebrafish rescue assay. Applications: Suitable for use in ELISA and Immunohistochemistry. Other applications not tested. Recommended Dilution: ELISA: 1:1,000, Immunohistochemistry: 1:50-1:100, Optimal dilutions to be determined by the researcher. Storage and Stability: Store product at 4°C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C. Aliquots are stable at -20°C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. , , Note: Applications are based on unconjugated antibody.